Patents Examined by Stacey N MacFarlane
  • Neural proteins as biomarkers for nervous system injury and other neural disorders
    Patent number: 10330689
    Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 25, 2019
    Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., BANYAN BIOMARKERS, INC.
    Inventors: Kevin Ka-Wang Wang, Monika Oli, Ming-Cheng Liu
  • Detecting a therapeutic cell
    Patent number: 10286092
    Abstract: The present invention relates to a method of detecting a therapeutic cell expressing a dopamine transporter (DAT) at a central nervous system (CNS) site in a subject, which comprises the administration of a DAT tracer to the subject, wherein the presence of a therapeutic cell which expresses the DAT is determined.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: May 14, 2019
    Assignee: UCL Business PLC
    Inventors: Martin Pulé, Adam Badar, Louise Kiru, Mark Lythgoe, Adrien Peters
  • Diagnostic method for parkinson's disease and lewy body dementia
    Patent number: 10281477
    Abstract: A method of detecting the presence, or monitoring the severity of a condition characterised by the presence of fragments of a marker protein in the brain of a patient. The method comprises: (i) providing a sample comprising macrophages obtained from the patient; and (ii) detecting the presence of the marker protein or fragments thereof in the macrophages. The presence of abnormal levels of the marker protein and/or fragments thereof in the macrophages is indicative of the presence of the condition in the patient. The condition and the marker proteins can be: Alzheimer's Disease and the Abeta peptide, Parkinson's Disease and ubiquitin, Multiple Sclerosis and myelin basic protein, FrontoTemporal Dementia and tau, Amyotrophic Lateral Sclerosis and tau, Parkinson's disease, Lewy Body dementia or Alzheimer's Disease and alpha-synuclein.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: May 7, 2019
    Assignee: INVEN2 AS
    Inventors: Tormod Fladby, Lisbeth Johnsen, Kaj Blennow
  • Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders
    Patent number: 10272142
    Abstract: Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: April 30, 2019
    Assignee: SHIRE VIROPHARMA INCORPORATED
    Inventors: Colin Broom, Jeffrey Dayno
  • Chemical reprogramming of human glial cells into neurons with small molecule cocktail
    Patent number: 10253293
    Abstract: Provided are compositions, articles and methods that relate to promoting neurogenesis or neuroregeneration in mammalian nervous system. Embodiments relate to use of groups of compounds that contain Crizotinib (Cri), Flurbiprofen, Lithium Chloride (Li), Vitamin C (VC), Ceritinib (Cer) or Pirfenidone (PFD). In certain implementations glial cells are converted into functional neurons.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: April 9, 2019
    Assignee: The Penn State Research Foundation
    Inventors: Gong Chen, Lei Zhang, Jiuchao Yin, Ningxin Ma
  • Composition comprising a culture solution of mesenchymal stem cells for the treatment of neural diseases
    Patent number: 10238692
    Abstract: Provided are a pharmaceutical composition for prevention and treatment of a neural disease including at least one selected from the group consisting of mesenchymal stem cells (MSCs), a culture solution of the MSCs, activin A, PF4, decorin, galectin 3, GDF15, glypican 3, MFRP, ICAM5, IGFBP7, PDGF-AA, SPARCL1, thrombospondin-1, WISP1, progranulin, IL-4, a factor inducing expression thereof, and any combination thereof, and a method therefor.
    Type: Grant
    Filed: November 16, 2009
    Date of Patent: March 26, 2019
    Assignee: MEDIPOST CO., LTD
    Inventors: Yoon-Sun Yang, Won II Oh, Jong Wook Chang, Ju Yeon Kim
  • Method of inhibiting microglial cell migration and treating traumatic brain injury
    Patent number: 10213480
    Abstract: Disclosed herein is a method of inhibiting microglial cell migration in the brain of a mammalian subject in need thereof, including subjects suffering from the symptoms of traumatic brain injury (TBI) and subjects suffering from a hematoma in the brain comprising administering an effective amount streptolysin O (SLO) wherein microglial migration is inhibited providing therapeutic benefits to subjects suffering from diseases characterized by microglial cell migration and activation.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: February 26, 2019
    Assignee: BEECH TREE LABS, INC.
    Inventor: John McMichael
  • Methods for estimating prion concentration in fluids and tissue by quantitative PMCA
    Patent number: 10215763
    Abstract: The present embodiments disclose methods for estimating PrPSc concentration in fluids and tissues by quantitative PMCA.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: February 26, 2019
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Claudio Soto, Baian Chen, Rodrigo Morales
  • Ameliorating nervous systems disorders
    Patent number: 10206953
    Abstract: The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: February 19, 2019
    Assignee: The Regents of the University of California
    Inventors: Arnold Kriegstein, John L. R. Rubenstein, Scott C. Baraban, Arturo Alvarez-Buylla
  • Biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders
    Patent number: 10203342
    Abstract: The present invention relates to biomarkers and diagnostic and prognostic methods for Alzheimer's disease and other neurodegenerative disorders. The invention also provides compositions for detecting the biomarker as well as compositions and methods useful for treating Alzheimer's disease and other neurodegenerative disorders.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: February 12, 2019
    Assignee: NANOSOMIX, INC.
    Inventor: Edward J. Goetzl
  • Na1.7 antibodies and methods of using the same
    Patent number: 10202450
    Abstract: Disclosed herein is an antibody that binds to a voltage sensor paddle (VSP) of Nav1.7. Also disclosed herein are methods of treating pain, itch, neurogenic inflammation, or cough in a subject in need thereof. The methods include administrating the antibody to the subject.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: February 12, 2019
    Assignee: Duke University
    Inventors: Seok-Yong Lee, Ru-Rong Ji
  • Methods of maintaining, expanding and differentiating neuronal subtype specific progenitors
    Patent number: 10160950
    Abstract: Methods for expanding proliferating populations of neuronal subtype-specific progenitors and creating substantially pure populations of motor neurons are provided herein. In particular, the present invention provides methods for maintaining the unique gene profile and differentiation potential of neuronal subtype-specific progenitors, such as motor neuron progenitors and hindbrain serotonergic neural progenitors.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: December 25, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Su-Chun Zhang, Zhongwei Du
  • Stem cells from the mammalian neural plate
    Patent number: 10160951
    Abstract: The present invention relates to methods for deriving novel stem cells from the mammalian early neural plate.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: December 25, 2018
    Inventor: Raja Kittappa
  • Treatment of central nervous system disorders by intranasal administration of immunoglobulin G
    Patent number: 10144776
    Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: December 4, 2018
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: William H. Frey, Leah Ranae Bresin Hanson, Sharon Pokropinski, Francisco M. Rausa
  • Inhibitors of valosin-containing protein and methods of use
    Patent number: 10143719
    Abstract: A method of inhibiting aberrant valosin-containing protein (VCP) accumulation in the mitochondria of a nerve cell includes administering to the nerve cell a therapeutic agent that inhibits the binding or complexing of VCP with a polyglutamine protein.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: December 4, 2018
    Assignee: Case Western Reserve University
    Inventor: Xin Qi
  • Composition comprising neural cell and elastin-like polypeptide for treating Parkinson's disease
    Patent number: 10137156
    Abstract: The present invention relates to a composition including neural cells and an elastin-like polypeptide for treating Parkinson's diseases. More particularly, the present invention relates to a composition for treating Parkinson's diseases, which can more effectively increase a survival rate and settling rate of neural cells transplanted to an acutely or chronically damaged nerve region for treatment of Parkinson's disease, by simultaneously administering an elastin-like polypeptide with neural cells.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: November 27, 2018
    Assignee: DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Won Bae Jeon, Jung-Hee Kim, Kyeong-Min Lee, Seong-Kyoon Choi
  • Combination therapy of stem cell mobilizing agents and stem cell transplantation
    Patent number: 10130683
    Abstract: A combined therapy of human umbilical cord blood cells (hUCB) and G-CSF at the acute stage of TBI was tested as a therapeutic for progressive secondary effects of chronic TBI. Rats were treated with saline carrier, or therapeutic in carrier as follows; G-CSF, hUCB, or hUCB and G-CSF, 7-days after TBI. Eight weeks later, behavioral testing was performed and brains harvested to analyze hippocampal cell loss, neuroinflammatory response, and neurogenesis. Results revealed that the monotherapies partially suppressed neuroinflammation and reduced hippocampal cell loss. However, combined therapy of hUCB and G-CSF robustly dampened neuroinflammation, while enhancing endogenous neurogenesis and reducing hippocampal cell loss. Vigorous and long-lasting recovery of motor function accompanied the combined therapy, which was either moderately or short-lived in the monotherapy conditions.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: November 20, 2018
    Assignee: University of South Florida
    Inventors: Cesario Venturina Borlongan, Paul R. Sanberg
  • Diagnostic biomarker profiles for the detection and diagnosis of alzheimer's disease
    Patent number: 10132817
    Abstract: The present invention provides methods, compositions and kits for the detection of Alzheimer's disease (AD) diagnostic biomarkers, for the diagnosis of AD, for the identification of a subject at risk for developing AD, and for the generation of patient-specific AD diagnostic biomarker profiles.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: November 20, 2018
    Assignee: Rowan University
    Inventor: Robert G. Nagele
  • Cellular test systems for the determination of the biological activities of neurotoxin polypeptides
    Patent number: 10125350
    Abstract: The present invention pertains to a method for the generation of neurotoxin-sensitive, neuronal differentiated cells comprising the steps of: a) cultivating tumor cells which are able to differentiate into neuronal cells in a culture medium under conditions and for a time which primes said tumor cells for neuronal differentiation; and b) cultivating the tumor cells primed for neuronal differentiation of a) in a differentiation medium having an osmolality of 100 to 270 mOsm/kg, and comprising (i) B27 supplement and/or (ii) N2 supplement, for at least 3 days, thereby obtaining neurotoxin-sensitive, neuronal differentiated cells. The invention further relates to neurotoxin-sensitive, neuronal differentiated cells obtainable by the method of the invention.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: November 13, 2018
    Assignee: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Karl-Heinz Eisele, Kai Harting
  • Neuregulin variants and methods of screening and using thereof
    Patent number: 10112983
    Abstract: The present invention provides polypeptide variants of neuregulin-1? (NRG-1?) that have enhanced or decreased binding affinity to ErbB3 and/or ErbB4. The invention also provides methods of screening and producing polypeptide variants of NRG-1? and methods of using polypeptide variants of NRG-1? for treating diseases.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: October 30, 2018
    Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.
    Inventor: Mingdong Zhou